Myocardial Ischemia
Conditions
Keywords
Acute Coronary Syndrome, Myocardial Infarction, Heart Attack, Angina, Chest pain, Ischemia, Non-ST Elevation Acute Coronary Syndrome
Brief summary
MERLIN-TIMI 36 is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in approximately 5,500 patients with non-ST elevation acute coronary syndromes (ACS) treated with standard therapy. The primary efficacy endpoint in MERLIN-TIMI 36 is time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia in patients with non-ST elevation ACS receiving standard therapy. The study also evaluates the safety of long-term treatment with ranolazine compared to placebo.
Detailed description
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006 Jun;151(6):1186.e1-9.
Interventions
DRUGRanolazine
IV to oral transition.
DRUGPlacebo
IV to oral transition.
Sponsors
The TIMI Study Group
Gilead Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hospitalized with non-ST elevation acute coronary syndrome * Ischemic symptoms (more than or equal to 5 minutes) at rest within 48 hours of study entry * At least one additional risk factor (e.g., elevated cardiac enzymes, ST-depression, diabetes)
Exclusion criteria
* Persistent acute ST-segment elevation * Successful revascularization during the qualifying hospitalization, prior to study entry * Acute pulmonary edema, hypotension, or evidence of cardiogenic shock * Clinically significant liver disease * End stage kidney disease requiring dialysis * Concomitant use of drugs known to prolong the QT interval, or any digitalis drugs * Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4 * Pregnant or lactating women, or women of child bearing potential not using an acceptable form of birth control Additional study entry criteria will be evaluated during initial screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction or recurrent ischemia through the end of the follow-up in non-ST elevation ACS. | First occurrence |
Secondary
| Measure | Time frame |
|---|---|
| Composite of cardiovascular death, myocardial infarction, or severe recurrent ischemia. Safety of long-term treatment with ranolazine compared to placebo; safety endpoints are death from any cause and symptomatic documented arrhythmia. | First occurence |
Countries
United States
Outcome results
None listed